SciELO - Scientific Electronic Library Online

 
vol.14 número7Rotación de morfina a metadona en domicilio: Descripción de 4 Casos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista de la Sociedad Española del Dolor

versión impresa ISSN 1134-8046

Resumen

ESCARTIN, R. et al. Buprenorphine local tolerability after the prophyplactic administration of antihistamine H1 antagonists. Rev. Soc. Esp. Dolor [online]. 2007, vol.14, n.7, pp.476-485. ISSN 1134-8046.

Introduction: One of the side effects of buprenorphine T.D.S, in an important percentage of patients, with bad local tolerability. Objetives: To evalúate the local tolerability of buprenorphine T.D.S., after the prophylactic administration of antihistamine Hl antagonists orally during the first month of treatment and after using topical therapy if the local irritation persisted. As well as its effectiveness along the time. Material and Method: A prospective observational study of 80 patients have been made (60 women and 20 men), age mediates 65.08 ±13.5 years (R 34-87), with osteoarticular chronic pain of modérate intensity. We checked the following 6 months. Controls: basal, 1, 2, 3 and 6 months. Dose: buprenorphine T.D.S between 17.5 and 70 µg/h every 3 days. doses mediate 37.84 ± 16.34 µg/h. All the patients began simultaneous treatment with cetirizina 10 mg/day orally in nocturnal unique dose during one month. Since them, we administered dimetindeno gel in those patients with persistence of exanthema, erythema or pruritus, when They stopped orally. It was valued like: 1. Good local tolerability only with orally: those patients who had not any local adverse reaction after one month of orally treatment and continué similar 6 months later. 2. Good local tolerability with orally + topical theraphy: those patients whom after suspending orally one month later, local adverse reaction persisted and after the topical theraphy administration, had not any local adverse reactions and continué similar 6 months later. 3. Regular local tolerability with orally + topical theraphy: those patients whom after suspending orally one month later, local adverse reaction persisted and after the topical teraphy administration had continued with slight and tolerable erythema and pruritus 6 months later. 4. Bad local tolerability only with orally: those patients whom after one month with orally treatment had severe erythema and pruritus and they had stopped treatment with buprenorphine T.D.S. 5. Bad local tolerability orally + topical theraphy: those patients whom after suspending orally one month later, persisted erythema and pruritus and after topical theraphy administration did not send the reaction adverse, stopping buprenorphine T.D.S. Results: GOOD: 56 patients (70%) orally only and orally + topical theraphy. FAIR: 7 patients (8.75%) orally + topical theraphy. BAD: 17 patients (21.25%) orally and orally + topical theraphy, they had suspended treatment. Conclusions: The results were good without local adverse reaction and persisting in the time in a high percentage of the patients following with the topical theraphy after one month orally. It had not any patient with local tumidity neither allergic reaction. It had not observed any variation of analgesic efficacy, so that, it had not changed of drug liberation because the previous topical theraphy of dimetindeno.

Palabras clave : Tolerability; Antihistamine H1 antagonists; Pruritus; Erythema.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons